Clinical Trial Update: PsA Treatment With hOKT3γ1 (Ala-Ala) [Phase 2]

View source ↗

Summary

Phase 2 trial of the immunomodulatory agent hOKT3γ1 (Ala-Ala) for psoriatic arthritis has been terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• hOKT3γ1 (Ala-Ala) (hOKT3γ1 (Ala-Ala))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Arthritis, Psoriatic | Phase 2 | Status: TERMINATED | Results posted: 2012-03-21